Application of AI and IoT in Clinical Medicine: Summary and Challenges.

The application of artificial intelligence (AI) technology in the medical field has experienced a long history of development. In turn, some long-standing points and challenges in the medical field have also prompted diverse research teams to continue to explore AI in depth. With the development of advanced technologies such as the Internet of Things (IoT), cloud computing, big data, and 5G mobile networks, AI technology has been more widely adopted in the medical field. In addition, the in-depth integration of AI and IoT technology enables the gradual improvement of medical diagnosis and treatment capabilities so as to provide services to the public in a more effective way. In this work, we examine the technical basis of IoT, cloud computing, big data analysis and machine learning involved in clinical medicine, combined with concepts of specific algorithms such as activity recognition, behavior recognition, anomaly detection, assistant decision-making system, to describe the scenario-based applications of remote diagnosis and treatment collaboration, neonatal intensive care unit, cardiology intensive care unit, emergency first aid, venous thromboembolism, monitoring nursing, image-assisted diagnosis, etc. We also systematically summarize the application of AI and IoT in clinical medicine, analyze the main challenges thereof, and comment on the trends and future developments in this field.

COVID-19 and the future of clinical epidemiology.

Clinical epidemiology, the "basic science for clinical medicine"[1], has changed substantially over the last 50 years, moving its focus from clinician driven research and clinical settings to large cohorts and trials, NIH funding, and practice guidelines. The COVID-19 pandemic created major challenges for clinicians who needed to make urgent decisions about the management a new disease and for researchers who needed to understand the clinical syndrome and the questions of greatest importance to the pandemic response. Addressing these challenges reunited clinicians and researchers in collaborative efforts to inform decisions about disease risk, prevention, prognosis and treatment, at least in part because of the shared sense of the need to ration scarce resources, the rapid evolution of understanding of the clinical syndrome, the recognition of widespread uncertainty, and the emphasis on the common good over individual credit. Only time will tell whether the experience during COVID-19 will revive the original practice of clinical epidemiology as "the application by a physician who provides direct patient care, of epidemiologic and biometric methods to the study of diagnostic and therapeutic process in order to effect an improvement in health"[2].

Clinical microbiology laboratories and COVID-19: an interview with Joseph Blondeau.

This interview was conducted by Atiya Henry, Commissioning Editor of Future Microbiology. Joseph M Blondeau, MSc, PhD, RSM(CCM), SM(AAM), SM(ASCP), FCCP is a Clinical Microbiologist and Head of Clinical Microbiology at Royal University Hospital (Saskatoon Health Region) and the University of Saskatchewan in Saskatoon, Canada. He is also the Provincial Clinical Lead for Microbiology in Saskatchewan, Canada. He holds a Masters of Sciences in Microbiology from Dalhousie University (1985) and a Doctor of Philosophy in Medical Microbiology from the University of Manitoba (1989). Following completion of his PhD, he completed an 1-month post-doctoral training in an infectious diseases research laboratory at Dalhousie University and following which he completed a 2-year post-doctoral residency training program in Clinical Microbiology, also at Dalhousie University. He holds appointments as a Clinical Associate Professor of Pathology, Adjunct Professor of Microbiology and Immunology and Clinical Associate Professor of Ophthalmology. He teaches to undergraduate and graduate students in the areas of microbiology, infectious diseases, antimicrobial agents and pharmacology. Dr Blondeau's main research interests are in the area of antimicrobial agents and antimicrobial resistance, clinical microbiology and clinical outcomes associated with antimicrobial therapy in both human and veterinary medicine.

The evolution of nerve growth factor inhibition in clinical medicine.

Nerve growth factor (NGF) is a neurotrophin that activates nociceptive neurons to transmit pain signals from the peripheral to the central nervous system and that exerts its effects on neurons by signalling through tyrosine kinase receptors. Antibodies that inhibit the function of NGF and small molecule inhibitors of NGF receptors have been developed and tested in clinical studies to evaluate the efficacy of NGF inhibition as a form of analgesia in chronic pain states including osteoarthritis and chronic low back pain. Clinical studies in individuals with painful knee and hip osteoarthritis have revealed that NGF inhibitors substantially reduce joint pain and improve function compared with NSAIDs for a duration of up to 8 weeks. However, the higher tested doses of NGF inhibitors also increased the risk of rapidly progressive osteoarthritis in a small percentage of those treated. This Review recaps the biology of NGF and the studies that have been performed to evaluate the efficacy of NGF inhibition for chronic musculoskeletal pain states. The adverse events associated with NGF inhibition and the current state of knowledge about the mechanisms involved in rapidly progressive osteoarthritis are also discussed and future studies proposed to improve understanding of this rare but serious adverse event.

A manifesto for the future of laboratory medicine professionals.

Laboratory medicine plays an increasingly essential role in modern healthcare systems, since it is integral to most care pathways and plays an essential role for optimizing patient flow, harmonizing procedures before and after analysis, improving harmonization and containing unnecessary testing. Nevertheless, recent changes in the nature of laboratory services, promoted by innovation and introduction of more complex tests in emerging diagnostic fields, more advanced diagnostics along with other "internal" and "external" drivers, will promote a paradigmatic transformation of current scenarios. The future of laboratory professionals remains hence uncertain, and is seems obvious that the role and figure of laboratory scientists and professionals shall evolve. We are hence proposing this 10-point "manifesto", which is aimed to encourage a new vision of the future of this discipline and should help supporting the development of a new generation of laboratory professionals and leaders, who shall be able to integrate specific technical and administrative skills with a broader vision of health care and patients needs.

Cohort Harmonization and Integrative Analysis From a Biomedical Engineering Perspective.

In this review, the critical parts and milestones for data harmonization, from the biomedical engineering perspective, are outlined. The need for data sharing between heterogeneous sources paves the way for cohort harmonization; thus, fostering data integration and interdisciplinary research. Unmet needs in chronic diseases, as well as in other diseases, can be addressed based on the integration of patient health records and the sharing of information of the clinical picture and outcome. The stratification of patients, the determination of various clinical and outcome features, and the identification of novel biomarkers for the different phenotypes of the disease characterize the impact of cohort harmonization in patient-centered clinical research and in precision medicine. Subsequently, the establishment of matching techniques and ontologies for the creation of data schemas are also presented. The exploitation of web technologies and data-collection tools supports the opportunities to achieve new levels of integration and interoperability. Ethical and legal issues that arise when sharing and harmonizing individual-level data are discussed in order to evaluate the harmonization potential. Use cases that shape and test the harmonization approach are explicitly analyzed along with their significant results on their research objectives. Finally, future trends and directions are discussed and critically reviewed toward a roadmap in cohort harmonization for clinical medicine.

Errores metodológicos frecuentes en la investigación clínica / Frequent methodological errors in clinical research

Se enumeran, discuten e ilustran diversos errores que se presentan con frecuencia en la investigación clínica. Se hace una distinción entre lo que puede considerarse un «error» surgido de la ignorancia o el descuido, de aquello que dimana de una falta de integridad de los investigadores, aunque se reconoce y documenta que no es fácil establecer cuándo estamos en un caso y cuándo en otro. El trabajo no se propone hacer un inventario exhaustivo de tales pifias, sino que se concentra en aquellas que, sin dejar de ser frecuentes, suelen ser menos evidentes o menos señaladas en los diversos listados que se han publicado con este tipo de problemas. Se ha optado por desarrollar en detalle los ejemplos que ilustran los problemas señalados en lugar de hacer una relación de errores acompañados de una descripción epidérmica de sus características

Several errors that are frequently present in clinical research are listed, discussed and illustrated. A distinction is made between what can be considered an "error" arising from ignorance or neglect, from what stems from a lack of integrity of researchers, although it is recognized and documented that it is not easy to establish when we are in a case and when in another. The work does not intend to make an exhaustive inventory of such problems, but focuses on those that, while frequent, are usually less evident or less marked in the various lists that have been published with this type of problems. It has been a decision to develop in detail the examples that illustrate the problems identified, instead of making a list of errors accompanied by an epidermal description of their characteristics

[Outstanding contribution of german professors J. Israel (18481926) and M. Nitze (18481906) to clinical urology (to the 170th anniversary of their birth)].

The article describes the achievements of James Israel and Max Nitze, who were successfully developing European medicine for more than 30 years of their scientific and practical activities, enriching it with both experimental and large clinical experience. Their scientific and practical accomplishments greatly contributed to the development of modern urology. The author analyzes the fact that the history of medicine gives rich material not only for understanding evolution but also for the possibility to foresee its further development. The current state of clinical urology has been achieved by the progress of basic research in biology, physics, biochemistry, bacteriology, immunology, pharmacology. At the same time, the personality of the scientist-physician, his observation, non-standard view, the ability to see the opening perspectives, to bring up worthy successors and create a scientific and clinical school of urologists, is of utmost importance. The great German urologists J. Israel and M. Nitze had all these fundamental characteristics of a great scientist-physician.

Human Disease/Clinical Medical Sciences in Dentistry: Current state and future directions of undergraduate teaching in the UK and Ireland.

In March 2017, a group of teachers of human disease/clinical medical science (HD/CMSD) representing the majority of schools from around the UK and Republic of Ireland met to discuss the current state of teaching of human disease and also to discuss how the delivery of this theme might evolve to inform improved healthcare. This study outlines how the original teaching in medicine and surgery to dental undergraduate students has developed into the theme of HD/CMSD reflecting changing needs as well as guidance from the regulators, and how different dental schools have developed their approaches to reach their current state. Each school was also asked to share a strengths, weakness, opportunities and threats (SWOT) analysis of their programme and to outline how they thought their HD/CMSD programme may develop. The school representatives who coordinate the delivery and assessment of HD/CMSD in the undergraduate curriculum have extensive insight in this area and are well-placed to shape the HD/CMSD development for the future.

[Recent Trends of Trace Element Studies in Clinical Medicine in Japan].

The deficiency or excess intake of trace elements, including zinc, copper, selenium and iodine, has often been reported. Zinc deficiency is often observed in infants fed breast milk with low zinc concentration, individuals administered chelating medicines, athletes and patients with diabetes mellitus, hepatic cirrhosis or nephrosis syndrome. Menkes disease is associated with severe copper deficiency, and there is no effective treatment. Deficiencies of selenium and iodine are observed in patients who receive special formulas of milk and enteral formula with low selenium and iodine concentrations, respectively. In contrast, neonatal transient hypothyroidism due to excess intake of iodine in pregnant women has also reported in Japan. It is expected that collaborative studies by researchers and clinicians will contribute to clarify the detail mechanism, diagnosis and treatment of these abnormalities.

Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic.

Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic, a Society of Toxicology Contemporary Concepts in Toxicology (CCT) workshop was held on March 11, 2017. The meeting was convened to raise awareness of metabolic syndrome and its associated diseases and serve as a melting pot with scientists of multiple disciplines (eg, toxicologists, clinicians, regulators) so as to spur research and understanding of this condition. The criteria for metabolic syndrome include obesity, dyslipidemia (low high-density lipoprotein and/or elevated triglycerides), elevated blood pressure, and alterations in glucose metabolism. It can lead to a greater potential of type 2 diabetes, lipid disorders, cardiovascular disease, hepatic steatosis, and other circulatory disorders. Although there are no approved drugs specifically for this syndrome, many drugs target diseases associated with this syndrome thus potentially increasing the likelihood of drug-drug interactions. There is currently significant research focusing on understanding the key pathways that control metabolism, which would be likely targets of risk factors (eg, exposure to xenobiotics, genetics) and lifestyle factors (eg, microbiome, nutrition, and exercise) that contribute to metabolic syndrome. Understanding these pathways could also lead to the development of pharmaceutical interventions. As individuals with metabolic syndrome have signs similar to that of toxic responses (eg, oxidative stress and inflammation) and organ dysfunction, these alterations should be taken into account in drug development. With the increasing frequency of metabolic syndrome in the general population, the idea of a "normal" individual may need to be redefined. This paper reports on the substance and outcomes of this workshop.

La Revista Española de Sanidad Penitenciaria como punto de encuentro entre profesionales: 20 años después / The Spanish Journal of Prison Health, a meeting point for professionals: 20 years later

No disponible

Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic.

Genome editing using clustered regularly interspersed short palindromic repeats (CRISPR) and CRISPR-associated proteins offers the potential to facilitate safe and effective treatment of genetic diseases refractory to other types of intervention. Here, we identify some of the major challenges for clinicians, regulators, and human research ethics committees in the clinical translation of CRISPR-mediated somatic cell therapy.